Literature DB >> 19548047

Effectiveness of prolonged fasting 18f-FDG PET-CT in the detection of cardiac sarcoidosis.

Rumman Langah1, Kenneth Spicer, Mulugeta Gebregziabher, Leonie Gordon.   

Abstract

BACKGROUND: The Japanese Ministry of Health and Welfare guidelines (JMHWG) are currently the standard used to diagnose cardiac sarcoidosis. JMHWG incorporate (67)Gallium scintigraphy as a minor criterion, while fasting (18)fluorine-2-fluoro-2-deoxy-D-glucose (FDG) PET is not included. As there is no published data comparing the accuracy of prolonged fasting FDG PET-CT (PF-PET) and Gallium scintigraphy for detecting active cardiac sarcoidosis, we sought to compare these two modalities. METHODS AND
RESULTS: We retrospectively reviewed medical records and nuclear images of 76 patients with suspected cardiac sarcoid who had either PF-PET or Gallium scintigraphy between January 2004 and August 2008. Eleven patients were excluded due to inadequate fasting for PF-PET, incomplete records or diagnosis other than sarcoid. Cardiac catheterizations, electrocardiogram interpretations, echocardiography reports, pathology reports, therapeutic interventions, and follow-up findings were correlated to PF-PET and Gallium scintigraphy results. Nuclear images of all patients including controls were reviewed independently by two experienced nuclear physicians blinded to results. Using JMHWG as reference standard, sensitivity, specificity, and accuracy of PF-PET were 85%, 90%, and 86.7% and for Gallium scintigraphy were 15%, 80%, and 42.8%.
CONCLUSIONS: Relative to Gallium scintigraphy, PF-PET appears to provide greater accuracy for detecting cardiac sarcoidosis. Our findings also highlight the importance of revising JMHWG to incorporate PF-PET and the importance of adequate prolonged fasting prior to FDG PET imaging.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19548047     DOI: 10.1007/s12350-009-9110-0

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  18 in total

1.  Technetium-99m sestamibi/tetrofosmin myocardial perfusion scanning in cardiac and noncardiac sarcoidosis.

Authors:  M Eguchi; K Tsuchihashi; D Hotta; A Hashimoto; H Sasao; S Yuda; T Nakata; N Shijubou; S Abe; K Shimamoto
Journal:  Cardiology       Date:  2000       Impact factor: 1.869

2.  The influences of blood glucose and duration of fasting on myocardial glucose uptake of [18F]fluoro-2-deoxy-D-glucose.

Authors:  H J Ding; Y C Shiau; J J Wang; S T Ho; A Kao
Journal:  Nucl Med Commun       Date:  2002-10       Impact factor: 1.690

3.  A prospective multi-centre study of the value of FDG-PET as part of a structured diagnostic protocol in patients with fever of unknown origin.

Authors:  Chantal P Bleeker-Rovers; Fidel J Vos; Aart H Mudde; Anton S M Dofferhoff; Lioe-Fee de Geus-Oei; Anton J Rijnders; Paul F M Krabbe; Frans H M Corstens; Jos W M van der Meer; Wim J G Oyen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-12-14       Impact factor: 9.236

4.  Mechanism of gallium 67 accumulation in inflammatory tissue.

Authors:  A Ando; K Nitta; I Ando; S Sanada; S Katsuda; N Tonami; T Hiraki; K Hisada; H Ogawa
Journal:  Eur J Nucl Med       Date:  1990

5.  Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis.

Authors:  Shinji Ishimaru; Ichizo Tsujino; Toshiki Takei; Eriko Tsukamoto; Shinji Sakaue; Mitsunori Kamigaki; Naofumi Ito; Hiroshi Ohira; Daisuke Ikeda; Nagara Tamaki; Masaharu Nishimura
Journal:  Eur Heart J       Date:  2005-04-04       Impact factor: 29.983

6.  Autoradiographic quantification of 18F-FDG uptake in experimental soft-tissue abscesses in rats.

Authors:  Achim H Kaim; Bruno Weber; Michael O Kurrer; Jochen Gottschalk; Gustav K Von Schulthess; Alfred Buck
Journal:  Radiology       Date:  2002-05       Impact factor: 11.105

7.  The additional value of gadolinium-enhanced MRI to standard assessment for cardiac involvement in patients with pulmonary sarcoidosis.

Authors:  Jan-Peter Smedema; Gabriel Snoep; Marinus P G van Kroonenburgh; Robert-Jan van Geuns; Emiel C Cheriex; Anton P M Gorgels; Harry J G M Crijns
Journal:  Chest       Date:  2005-09       Impact factor: 9.410

8.  Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis.

Authors:  Wataru Okumura; Tsutomu Iwasaki; Takuji Toyama; Tatsuya Iso; Masashi Arai; Noboru Oriuchi; Keigo Endo; Tomoyuki Yokoyama; Tadashi Suzuki; Masahiko Kurabayashi
Journal:  J Nucl Med       Date:  2004-12       Impact factor: 10.057

9.  Metabolic fate of extracted glucose in normal human myocardium.

Authors:  J A Wisneski; E W Gertz; R A Neese; L D Gruenke; D L Morris; J C Craig
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

10.  Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet.

Authors:  Gethin Williams; Gerald M Kolodny
Journal:  AJR Am J Roentgenol       Date:  2008-02       Impact factor: 3.959

View more
  50 in total

1.  Suppression of myocardial 18F-FDG uptake with a preparatory "Atkins-style" low-carbohydrate diet.

Authors:  Richard Coulden; Peter Chung; Emer Sonnex; Quazi Ibrahim; Conor Maguire; Jon Abele
Journal:  Eur Radiol       Date:  2012-05-18       Impact factor: 5.315

2.  Dual gated PET/CT imaging of small targets of the heart: method description and testing with a dynamic heart phantom.

Authors:  Tommi Kokki; Hannu T Sipilä; Mika Teräs; Tommi Noponen; Nicolas Durand-Schaefer; Riku Klén; Juhani Knuuti
Journal:  J Nucl Cardiol       Date:  2010 Jan-Feb       Impact factor: 5.952

3.  Fasting FDG PET compared to MPI SPECT in cardiac sarcoidosis.

Authors:  Scott C Brancato; James A Arrighi
Journal:  J Nucl Cardiol       Date:  2011-04       Impact factor: 5.952

Review 4.  Recommendations for 18F-fluorodeoxyglucose positron emission tomography imaging for diagnosis of cardiac sarcoidosis-2018 update: Japanese Society of Nuclear Cardiology recommendations.

Authors:  Shinichiro Kumita; Keiichiro Yoshinaga; Masao Miyagawa; Mitsuru Momose; Keisuke Kiso; Tokuo Kasai; Masanao Naya
Journal:  J Nucl Cardiol       Date:  2019-08       Impact factor: 5.952

5.  Joint SNMMI-ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring.

Authors:  Panithaya Chareonthaitawee; Rob S Beanlands; Wengen Chen; Sharmila Dorbala; Edward J Miller; Venkatesh L Murthy; David H Birnie; Edward S Chen; Leslie T Cooper; Roderick H Tung; Eric S White; Salvador Borges-Neto; Marcelo F Di Carli; Robert J Gropler; Terrence D Ruddy; Thomas H Schindler; Ron Blankstein
Journal:  J Nucl Cardiol       Date:  2017-10       Impact factor: 5.952

6.  Importance of extracardiac FDG uptake to diagnose cardiac sarcoidosis.

Authors:  Nobuhiro Tahara; Munehisa Bekki; Yoichi Sugiyama; Atsuko Tahara; Yoshihiro Fukumoto
Journal:  J Nucl Cardiol       Date:  2018-09-05       Impact factor: 5.952

7.  Management of cardiac sarcoidosis in the United States: a Delphi study.

Authors:  Nabeel Y Hamzeh; Frederick S Wamboldt; Howard D Weinberger
Journal:  Chest       Date:  2011-07-07       Impact factor: 9.410

8.  Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis.

Authors:  Azadeh Ahmadian; Ashley Brogan; Jeffrey Berman; Aaron L Sverdlov; Gustavo Mercier; Michael Mazzini; Praveen Govender; Frederick L Ruberg; Edward J Miller
Journal:  J Nucl Cardiol       Date:  2014-05-31       Impact factor: 5.952

9.  Continuing evolution in preparation protocols for 18FDG PET assessment of inflammatory or malignant myocardial disease.

Authors:  John P Bois; Panithaya Chareonthaitawee
Journal:  J Nucl Cardiol       Date:  2016-03-25       Impact factor: 5.952

Review 10.  Clinical use of biomarkers of survival in pulmonary fibrosis.

Authors:  Michiel Thomeer; Jan C Grutters; Wim A Wuyts; Stijn Willems; Maurits G Demedts
Journal:  Respir Res       Date:  2010-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.